hVIVO strengthens Board with appointment of Richard Cotton as Non-Executive Director Seasoned life sciences executive with extensive Board and financial expertise
Poolbeg Pharma (AIM: POLB) Letter to Shareholders – 2025 a year of progress
Letter to Shareholders – 2025 a year of great progress, with momentum maintained into 2026 when multiple value inflection points are expected
Avacta Therapeutics (AIM: AVCT) reports new AVA6103 pharmacology data
Avacta reports new pharmacology data for FAP-Exd (AVA6103) Multiple patient-derived xenograft models with prolonged complete responses associated with sustained release of the exatecan payload within the tumor over five days
GENinCode Plc (AIM: GENI) CARDIO inCode-Score® distribution with Sohin Genetics, Mexico
GENinCode Plc has entered into a commercial agreement with Sohin Genetics in Mexico to distribute its CARDIO inCode-Score® Polygenic Risk Score test, which is designed to help predict and prevent
Early trial success for Avacta (AIM: AVCT) as AVA6000 shows meaningful tumor responses
Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers Preliminary Phase 1b data is in line with Phase 1a data reported at the European Society
Genflow Biosciences Plc (LON: GENF) Completion of Dosing Phase of Canine Gene Therapy
Genflow Completes Dosing Phase of Canine Gene Therapy Trial No Adverse Events Reported During Administration
Shore Capital Reaffirms Buy Rating on hVIVO Despite Share Price Weakness
Shore Capital has maintained its Buy rating on hVIVO PLC, the specialist contract research organisation, with a fair value assessment of 25 pence per share.
genedrive plc (LON: GDR) New interactive investor hub
genedrive plc launches new interactive investor hub
Genflow Biosciences Plc (LON: GENF) to pitch longevity gene therapy at JPM 2026
Genflow to Attend the 44th Annual J.P. Morgan Healthcare Conference
Avacta Therapeutics (AIM: AVCT) Preliminary Data in Faridoxorubicin Phase 1b Trial
Avacta Announces the Preliminary Clinical Data in the Faridoxorubicin Phase 1b Trial in the Salivary Gland Cancer Cohort
Poolbeg Pharma (AIM: POLB) POLB 001 to feature in CRS research programme
POLB 001 trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme RISE programme led by The University of Manchester and The Christie NHS Foundation Trust and funded in part
Welcome Dr. Christina Coughlin, CEO of Avacta Therapeutics, onto The BioHub!
Welcome to the Avetix Group YouTube channel.